



Citi Pharma Limited

April 28, 2023

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the 3rd quarter ended March 31, 2023

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on April 28, 2023 at Lahore have approved the financial statements for the 3rd Quarter ended on March 31, 2023 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil


Financial results of the company for the first quarter ended March 31, 2023 are enclosed.

Quarterly report of the Company for the quarter ended March 31, 2023 will be transmitted through PUCARS separately, within the specified time.

Other:

We are pleased to inform you that M/s Digital Custodian Company Limited is hereby appointed as Share Registrar of the Company in place of F.D Registrar Services (Pvt.) Limited with effect from May 01, 2023.

Yours Sincerely,


Muhammad Riaz
Company Secretary
& Head of Legal



Cc:

Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2023

	Three month ended		Nine Months Ended	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
	-----Rupees-----			
Sales- Net	2,688,727,730	2,748,139,247	8,859,599,815	7,589,370,656
Cost of Sales	(2,338,312,529)	(2,394,782,158)	(7,593,756,702)	(6,534,612,959)
Gross Profit	350,415,201	353,357,089	1,265,843,113	1,054,757,697
Administrative Expenses	38,666,898	35,229,626	140,255,722	238,950,314
Selling Expenses	23,395,988	6,296,697	93,878,262	60,656,610
	(62,062,886)	(41,526,323)	(234,133,984)	(299,606,924)
Operating Profit	288,352,315	311,830,765	1,031,709,129	755,150,774
Financial (Cost) /income	(156,023,397)	(18,206,305)	(277,626,004)	(52,333,402)
	132,328,917	293,624,461	754,083,124	702,817,371
Other Income/(Loss)	17,328,987	45,264,633	69,862,576	134,519,491
	149,657,905	338,889,094	823,945,701	837,336,862
Other Expenses	(10,476,053)	(23,722,237)	(52,846,538)	(57,082,702)
Profit Before Taxation	139,181,851	315,166,857	771,099,162	780,254,160
Taxation	(46,415,756)	(107,717,629)	(237,696,142)	(229,563,711)
Profit for the Period	92,766,096	207,449,228	533,403,021	550,690,450
Earnings per share (EPS)				
- Basic and Diluted	0.41	0.92	2.33	2.43



Handwritten signature



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk